Lundin K, Karlsson A, Nygren A, Löfström A, Gigliotti D, Wigzell H
Department of Immunology, Karolinska Institute, Stockholm, Sweden.
Scand J Immunol. 1988 Jan;27(1):113-7. doi: 10.1111/j.1365-3083.1988.tb02328.x.
HIV+ human sera contain antibodies against most HIV proteins, including the envelope glycoprotein Gp120. Some of these antibodies may have an epitope that sterically resembles the CD4 region to which the Gp120 molecule binds. Amongst 58 HIV+ sera tested, we found three with the capacity to block the binding of anti-CD4 monoclonal antibodies to CD4+ cells. The serum with the highest blocking capacity was selected for further analysis. The inhibitor was shown to be an antibody that binds to the Gp120 molecule as well as to the anti-CD4 monoclonal T4.2. These CD4-mimicking antibodies were shown not to interfere with CD4-dependent reactions in vitro. Virus neutralizing experiments in vitro could not show any neutralizing effect with these antibodies alone. The HIV+ individual providing this antibody is still healthy, although HIV+ since 1983.
感染HIV的人血清中含有针对大多数HIV蛋白的抗体,包括包膜糖蛋白Gp120。其中一些抗体可能具有一个表位,其空间结构类似于Gp120分子结合的CD4区域。在检测的58份感染HIV的血清中,我们发现三份血清具有阻断抗CD4单克隆抗体与CD4+细胞结合的能力。选择阻断能力最强的血清进行进一步分析。结果表明,该抑制剂是一种既能结合Gp120分子又能结合抗CD4单克隆抗体T4.2的抗体。这些模拟CD4的抗体在体外不会干扰依赖CD4的反应。体外病毒中和实验表明,单独使用这些抗体没有任何中和作用。提供这种抗体的HIV感染者自1983年感染以来仍保持健康。